Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Four Injectable Neuromodulators in the Glabella Area
NCT05167864Completed
- Sponsor
- University of Pennsylvania
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial of botulinum toxin type A in glabellar lines (4 arms), sponsored by University of Pennsylvania. Primary endpoint: Change in Dynamic Strain in the Glabella Area After Injection Over Time at Day 180. Started Mar 2022; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05167864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167864.